Yazar "Guler, Tunc" seçeneğine göre listele
Listeleniyor 1 - 10 / 10
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cancer types attributable to cigarette smoking and sociodemographic characteristics(Kare Publ, 2014) Kutlu, Ruhusen; Demirbas, Nur; Boruban, Melih Cem; Guler, TuncOBJECTIVES This study was performed to evaluate the sociodemographic characteristics, smoking status and the frequency of the cancer types attributable to cigarette smoking in the cancer patients treating at Medical Oncology Department. METHODS This descriptive and cross-sectional study was performed among 459 cancer inpatients treating at Medical Oncology Department. Data were obtained via a questionnaire form revealed socio-demographic characteristics, smoking-related attitude and behaviors. RESULTS Of the participants, the mean age was 57.42 +/- 13.29 (range: 1891), 52.9% were male. The prevalence of current smokers was 9.6%, former smokers 48.1%, never-smokers 42.3%. respectively. While respiratory tract cancers (32.1%), GIS (24.3%) and colorectal cancers (18.9%) were seen frequently in the male gender, breast cancer (46.8%) GIS cancers (15.3%) and colorectal cancers (12.5%) were seen frequently in the female. While the frequency of the respiratory tract cancers was 30.6% in the smoker cancer patients, this rate was 4.6% in never smokers. The frequency of the respiratory tract cancers was higher in the smoker cancer patients than never smoker cancer patients (RR=6.65). Of the respiratory tract cancers, 26.0% was attributed to cigarette smoking. CONCLUSION Particularly, smoking plays an important role in the development of lung cancer. Common cancers shows differences according to gender and age. So, the socio-demographic characteristics should be considered while the cancer screening programs are developing.Öğe Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases(Sage Publications Ltd, 2014) Artac, Mehmet; Koral, Lokman; Toy, Hatice; Guler, Tunc; Boruban, Melih C.; Altundag, KadriPresentation with bone marrow metastasis at diagnosis is a rare event in breast carcinoma. Here, we report a rare presentation of metastatic breast cancer patient with bone marrow metastases, who was successfully treated with trastuzumab combined chemotherapy. The regimens initially applied for bone marrow metastasis were docetaxel/adriamycin, gemcitabine/vinorelbine, epirubicin/cyclophosphamide, capecitabine, docetaxel, gemcitabine, and paclitaxel. But, the best response to these regimens was not satisfactory. Our patient was completely treated with etoposide-cisplatin and trastuzumab combination. She is still on remission after five years of metastatic breast cancer diagnosis using letrozole and trastuzumab without complication. Physicians should be careful in treating bone marrow metastases in breast cancer, since patients can show improved marrow function after chemotherapy and long-lasting survival is possible.Öğe THE EFFCT OF METFORMIN USE ON PROGNOSIS IN PANCREATIC CANCER PATIENTS(Carbone Editore, 2014) Esbah, Onur; Eren, Tulay; Helvaci, Kaan; Guler, Tunc; Duran, Ayse Ocak; Bal, Oznur; Ozdemir, Nuriye YildirimBackground: Several clinical studies have shown the effect of mefformine on survival in pancreatic cancer. We aimed to evaluate whether the use of mefformin in diabetic pancreatic cancer patients provides a survival advantage or not. Methods: The data of 467 pancreatic adenocarcinoma patients diagnosed between 2003 and 2012 from five centers were analyzed, retrospectively. The groups were pancreatic cancer patients with diabetes who use metfonnin, who don't use metfornzin and non-diabetics. Results: Median overall survival was 8 months for the whole cohort, and 8 months for the group of non-diabetic patients. Overall survival was 8 months for the diabetic patients who use metfonnin whereas 10 months for the patients who do not use metformin. There was no statistically significant survival difference between the groups (p:0,76). Conclusion: Our study did not support clinical benefit of metformin in diabetic pancreatic cancer patients.Öğe Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis(Modestum Ltd, 2012) Boruban, Cem; Gulyer, Huseyin; Altundag, Kadri; Artac, Mehmet; Guler, Tunc; Cengiz, MustafaCNS metastases usually appears late in the progression of metastatic breast cancer. Classical approach is evaluating and treating them when symptoms become evident. We evaluated the survival and described clinicopathologic characteristics of patients in whom the brain metastases after adjuvant treatment or at initial diagnosis are the first and the only side. Authors retrospectively evaluated about 3600 patients with breast cancer treated in two university hospitals. In those 31 patients with first and only metastases to brain and no other metastases were evaluated. ER, PR, cerbB2 status T, N stage, grade, adjuvant taxane, trastuzumab, hormonal treatment, trastuzumab and platine use after brain metastases didn't effect the survival. Surgery and WBRT may be more effective in cerbB2 negative patients, WBRT in cerbB2 positive ones. (p=0.06). The survival outcome may be better in pre and perimenouposal women. The mOS of pre and perimenopausal, postmenopausal women were 17.7 months and 10.3 months respectively (p=0.06) and lapatinib may affect the mOS of patients with isolated brain metastases. Some prognostic factor may help us to foresee which group may benefit more from which treatment modality. The need for studies with larger groups of patients is obvious.Öğe Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.(Lippincott Williams & Wilkins, 2013) Esbah, Onur; Oksuzoglu, Berna; Eren, Tulay; Helvaci, Kaan; Guler, Tunc; Duran, Ayse Ocak; Bal, Oznur[Abstract Not Availabe]Öğe Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab(Springer, 2017) Artac, Mehmet; Uysal, Mukremin; Karaagac, Mustafa; Korkmaz, Levent; Er, Zehra; Guler, Tunc; Boruban, Melih CemPurpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev. Methods This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and Creactive protein (CRP) were recorded before FOLFIRI-bev therapy. The efficacy of these factors on progression-free survival (PFS) was analyzed with Kaplan Meier and Cox regression analysis. And the cutoff value of N/L ratio was analyzed with ROC analysis. Results The median age was 56 years (range 21-80). Forty-seven percent of patients with N/L ratio >2.5 showed progressive disease versus 43 % in patients with N/L ratio <2.5 (p = 0.025). The median PFS was 8.1 months for the patients with N/L ratio >2.5 versus 13.5 months for the patients with N/L ratio <2.5 (p = 0.025). At univariate Cox regression analysis, high baseline neutrophil count, LDH, N/L ratio, and CRP were all significantly associated with poor prognosis. At multivariate Cox regression analysis, CRP was confirmed to be a better independent prognostic factor. CRP variable was divided into above the upper limit of normal (ULN) and normal value. The median PFSs of the patients with normal and above ULN were 11.3 versus 5.8 months, respectively (p = 0.022). Conclusions CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev.Öğe The prognostic role of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in resected non-small cell lung cancer (NSCLC)(Lippincott Williams & Wilkins, 2013) Geredeli, Caglayan; Artac, Mehmet; Yildirim, Selman; Dede, Isa; Inal, Ali; Guler, Tunc; Boruban, Melih Cem[Abstract Not Availabe]Öğe Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer(Sage Publications Ltd, 2015) Geredeli, Caglayan; Artac, Mehmet; Yildirim, Selman; Inal, Ali; Dede, Isa; Guler, Tunc; Boruban, Melih CemIdentification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8-35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6-75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0-127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6-88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.Öğe Relation of metastatic stage at the diagnosis of non-small cell lung cancer (NSCLC) to XRCC1 and TP53 single nucleotide polymorphisms (SNPs)(Lippincott Williams & Wilkins, 2014) Artac, Mehmet; Geredeli, Caglayan; Yildirim, Selman; Dede, Isa; Ina, Ali; Guler, Tunc; Boruban, Mellh Cem[Abstract Not Availabe]Öğe Relation of metastatic stage at the diagnosis of non-small cell lung cancer (NSCLC) to XRCC1 and TP53 single nucleotide polymorphisms (SNPs)(Lippincott Williams & Wilkins, 2014) Artac, Mehmet; Geredeli, Caglayan; Yildirim, Selman; Dede, Isa; Ina, Ali; Guler, Tunc; Boruban, Mellh Cem[Abstract Not Availabe]
